MarketPulse

autoimmune disease

6 articles
BenzingaBenzinga··Vandana Singh

Gilead Bolsters Inflammation Arsenal With $1.675B Ouro Medicines Deal

Gilead acquires Ouro Medicines for $1.675B upfront, targeting inflammation pipeline expansion. Galapagos NV partners to co-develop lead asset OM336.
GILDACLXGLPGacquisitionorphan drug designation
BenzingaBenzinga··Globe Newswire

SAB Biotherapeutics Raises $85M to Advance Type 1 Diabetes Treatment

SAB Biotherapeutics prices $85M offering at $3.85/share to fund Phase 2b trials of type 1 diabetes candidate SAB-142, with closing expected March 2026.
SABSSABSWclinical trialpublic offering
BenzingaBenzinga··Vandana Singh

Novartis Expands Cosentyx Reach Into Pediatric Dermatology With FDA Approval

Novartis wins FDA approval for Cosentyx in pediatric hidradenitis suppurativa patients aged 12+, marking the drug's fourth pediatric indication and expanding its dermatology portfolio.
NVSFDA approvalautoimmune disease
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

Argenx's Vyvgart Poised for Explosive Growth as Autoimmune Market Expands

Argenx's Vyvgart gains momentum with Japan approval and Fujifilm partnership, positioning the FcRn inhibitor for significant market expansion across multiple autoimmune indications through 2030.
ARGXFUJIYVYVGARTbiologic therapy
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Dianthus to Unveil Phase 3 CIDP Trial Data as Claseprubart Nears Potential Breakthrough

Dianthus Therapeutics will present interim responder analysis from Phase 3 CAPTIVATE trial of claseprubart for CIDP treatment on March 9, 2026.
DNTHclinical-stage biotechPhase 3 trial
GlobeNewswire Inc.GlobeNewswire Inc.··Argenx Se

argenx's VYVGART Meets Primary Endpoint in Ocular Myasthenia Gravis Trial

argenx's VYVGART met its primary endpoint in a Phase 3 ocular myasthenia gravis trial, showing significant symptom improvements. The company plans FDA approval for label expansion.
ARGXFDA approvalPhase 3 trial